1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Granules India Limited

Granules India Limited

GRANULES.NS
Granules India LimitedIN flagNational Stock Exchange of India
900.45
INR
+10.60
- -
223.13BMarket Cap
Granules India Limited
GRANULES.NS
(National Stock Exchange of India)

Recent

price

900.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
23.69
32.6
38.05
54.19
63.43
65.58
64.42
67.65
87.93
100.11
128.25
150.39
183.22
185.38
183.83
219.56
219.46
Revenue per Share
1.04
1.49
1.62
3.72
4.46
5.95
7.52
5.49
9.3
13.19
22.05
16.65
21.05
16.73
20.69
24.47
24.46
Basic EPS, GAAP
1.18
-1.47
-1.26
-7.85
0.11
-0.52
-5.87
-18.5
-0.68
11.47
6.47
-2.65
13.37
2.43
12.16
9.67
- -
Free Cash Flow per Basic Share
0.15
0.17
0.23
0.23
0.41
1.13
1.02
1.2
1.21
1.21
0.99
1.5
0.76
1.5
1.5
1.5
- -
Dividend per Share
1.08
5.96
7.23
5.55
4.74
9.55
11
14.35
21.75
33.72
55.43
70.89
91.86
108.22
127.22
1.02
1.02
Book Value per Share
10.96
11.36
13.02
12.27
16.87
28
31.57
41.54
45.66
58.3
74.57
92.21
103.66
122.78
144.53
200.82
200.73
Tangible Book Value per Share
201
201
201
202
204
207
219
242
254
254
249
248
245
242
242
243
243
Basic Weighted Avg Shares
4,752
6,540
7,644
10,959
12,929
13,555
14,097
16,345
22,344
25,452
31,960
37,272
44,963
44,902
44,560
53,389
53,389
Sales/Revenue/Turnover
8.15
9.18
8.31
11.89
12.16
16.31
16.52
12.44
12.49
16.68
22.39
15.42
16.41
14.71
16.15
16.65
16.65
Operating Margin (%)
183
207
231
298
527
584
715
762
1,055
1,370
1,515
1,586
1,845
2,073
2,255
2,961
2,961
Depreciation Expense
209
300
326
752
909
1,230
1,645
1,326
2,364
3,354
5,495
4,128
5,166
4,053
5,015
5,950
5,950
Net Income, GAAP
21.9
30.3
29.7
33.05
28.96
32.87
28.38
32.35
27.37
25.65
21.99
26.03
24.82
25.93
24.03
24.2
24.2
Effective Tax Rate (%)
4.4
4.58
4.26
6.87
7.03
9.07
11.67
8.11
10.58
13.18
17.19
11.07
11.49
9.03
11.25
11.14
11.14
Profit Margin (%)
1,299
466
831
844
798
1,633
410
3,087
3,858
7,353
8,239
8,634
7,606
8,228
11,123
16,756
16,756
Working Capital
1,372
881
1,755
3,092
2,427
1,842
1,242
4,331
4,788
4,215
3,411
2,420
2,192
1,522
4,707
4,581
4,581
LT Debt
2,198
2,451
2,749
3,560
4,308
6,616
9,036
13,042
15,295
18,437
21,733
25,871
28,349
32,255
37,156
50,850
50,850
Total Equity
8.57
10.37
8.96
12.94
12.35
13.22
11.92
7.13
8.44
12.09
19.49
12.72
14.53
11.55
11.31
11.47
11.47
Return on Invested Capital (%)
18.77
16.23
11.25
17.55
18.09
19.88
22.01
13.45
17.56
21.35
28.38
16.55
17.37
12.51
13.69
22.44
22.44
Return on Capital (%)
96.11
42.39
24.6
58.42
87.03
83.7
75.12
45.14
52.57
47.58
49.09
26.3
25.76
16.63
17.58
38.28
38.28
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
13,303
- -
10,539
LT Borrowings
3,176
- -
2,972
LT Finance Leases
1,591
- -
1,610
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
- -
248
Market Capitalization
125,433
145,234
150,927

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
30,869
- -
37,676
Cash, Cash Equivalents & STI
6,257
- -
9,535
Accounts Receivable, Net
7,605
- -
9,094
Inventories
14,883
- -
16,730
Total Current Liabilities
24,173
- -
20,920
Payables & Accruals
- -
- -
- -
ST Debt
13,303
- -
10,539
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.11%
18.89%
36.86%
Free Cash Flow
-104.2%
-88.33%
-20.29%
Net Income, GAAP
21.95%
4.22%
18.64%
Sales/Revenue/Turnover
15.23%
11.23%
19.81%
Total Cash Common Dividend
10.73%
19.13%
0.12%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,855
11,880
11,497
11,596
44,902
2025
11,799
9,565
11,335
11,968
44,560
2026
12,088
12,947
13,780
14,574
53,389

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.98
4.22
5.18
- -
16.73
2025
5.56
4.01
4.85
6.27
20.69
2026
4.64
5.38
6.19
8.23
24.47

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.5
2025
- -
- -
- -
- -
1.5
2026
- -
- -
- -
- -
1.5
Similar Companies
Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS)
ManifestSeven Holdings Corporation (MNFSF)
Real Brands, Inc. (RLBD)
Columbia Care Inc. (CCHWF)
Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
Business
Granules India Limited, a vertically integrated pharmaceutical manufacturer, produces active pharmaceutical ingredients including paracetamol, ibuprofen, metformin, guaifenesin and methocarbamol; pharmaceutical formulation intermediates; and finished dosages such as tablets, caplets and press-fit capsules in bulk, blister packs and bottles, with additional capabilities in oncology APIs forward-integrated into finished forms, multiple unit pellet systems, modified and delayed release technologies, and peptide-based therapeutics. Headquartered in Hyderabad, Telangana, India, and founded in 1984, the company operates 10 manufacturing facilities primarily in India, including the world's largest PFI facility in Gagillapur, a joint venture in Wuhan, China, and serves over 300 customers in more than 80 countries through subsidiaries like Granules Life Sciences Private Limited. In early 2025, Granules completed the acquisition of Senn Chemicals AG, a Swiss CDMO specializing in peptides, for CHF 20 million to enter the high-growth peptide segment including GLP-1 receptor agonists for anti-diabetic and anti-obesity markets; in November 2025, its Hyderabad facility secured the first U.S. FDA approval for Metformin HCl following a pre-approval inspection, enabling U.S. product launch and multi-site manufacturing for enhanced market share and business continuity; the company also advances green pharmaceutical zones in collaboration with Greenko in Kakinada, Andhra Pradesh, and plans FY26 expansions in CNS/ADHD, oncology and oligonucleotides via the acquired entity.